Perimenopause App Quality: Why Most Menopause Apps Score 3.1 out of 5

DEFINITION

Evidence-based app

An app with features grounded in clinical research and involving healthcare professionals in its design, content review, or validation process. In the Birkby et al. systematic review, only 22.7% of menopause apps met this criteria, meaning the remaining 77.3% were built without documented clinical input or research foundation.

The Quality Problem

In 2023, Birkby and colleagues published a systematic review in BMC Women’s Health evaluating 28 menopause-related apps against standardized quality criteria. The mean score was 3.1 out of 5.

A 3.1 is mediocre. These apps handle sensitive health data for a condition affecting roughly 1.3 million US women entering menopause each year. Mediocre is not good enough when the data includes hormonal symptoms, mood patterns, sexual function, and reproductive status.

Only 22.7% of evaluated apps qualified as evidence-based, meaning healthcare professionals participated in design and features were grounded in clinical research. The other 77.3% were built without documented clinical input. They are wellness tools marketed as health tools.

What “Evidence-Based” Means and Why 77.3% Fail

“Evidence-based” is not a marketing label. In the Birkby review, it meant specific things: clinical professionals participated in app design or content review, features were grounded in published research, and there was some form of validation process.

Most menopause apps fail this standard because they started as something else. Period trackers added menopause modes. General wellness apps bolted on symptom checklists. The underlying architecture was designed for regular, predictable cycles — precisely what perimenopause disrupts.

A period tracker that assumes a 28-day cycle and asks you to log your period start date is architecturally wrong for perimenopause, where cycles might range from 14 to 90 days, skip for months, then return. The tracking model encodes the wrong assumptions about the user’s body.

Without clinical input, apps track the wrong things. Hot flashes and missed periods get tracked because that is the popular understanding of menopause. But perimenopause also produces cognitive changes, joint pain, sleep disruption, anxiety, heart palpitations, and dozens of other symptoms that many apps ignore entirely. If you cannot track it, you cannot show it to your doctor. And if you cannot show it, the conversation starts with gaps.

The Privacy Problem

Quality is not just features. It is what happens to the data you enter.

Flo Health, the most downloaded period tracker globally, settled with the FTC in 2021 after sharing user health data with Facebook and Google analytics without adequate consent. The data included pregnancy status, cycle information, and health symptoms — shared with advertising platforms.

Flo is not alone. Caria (formerly Clio), a menopause-specific app, stores data on AWS cloud infrastructure. Many menopause apps have privacy policies that permit data sharing with third-party analytics providers, advertising networks, or research partners, sometimes buried in terms-of-service language that few users read in full.

For perimenopause tracking, the privacy stakes are higher than for a step counter. The data reveals your age-related health status, hormonal conditions, mood and cognitive patterns, and reproductive details. Advertisers love this stuff for demographic targeting, and most users would rather control it themselves.

The Birkby review did not specifically weight privacy in its quality scoring, which means the 3.1 average does not fully capture the problem. An app could score well on engagement and functionality while selling your data to third parties.

The Compliance Problem

Even when an app tracks the right symptoms, you have to actually use it for the data to matter.

A 2003 study by Stone and colleagues, published in Controlled Clinical Trials, equipped paper diaries with hidden sensors to detect when participants opened them. Participants self-reported 94% compliance. The sensors showed actual compliance was 11%.

Digital tools close this gap substantially. The same study found that electronic diaries achieved genuine compliance rates above 90%. The device prompts you. The timestamp is automatic. The friction of recording is lower than opening a notebook and writing entries.

For perimenopause tracking, compliance matters because the clinical value comes from pattern detection over weeks, not individual data points. A provider needs to see mood scores correlated with cycle phase, vasomotor symptoms mapped against sleep quality, cognitive changes tracked with enough regularity to distinguish pattern from noise. Sporadic entries do not generate that picture.

Digital apps should be winning here. The medium supports better compliance than paper. But the 3.1 quality score suggests most apps are squandering that advantage. They are not designing tracking workflows that make daily entry fast, thorough, and clinically useful.

What to Look For

If you are evaluating menopause or perimenopause tracker apps, five criteria separate useful tools from the 77.3% that lack clinical foundation.

Privacy model. Where is your data stored? On your device only, or on company servers? Does the privacy policy explicitly state that data is not sold or shared with advertisers? If the privacy policy is vague or permits third-party sharing, assume the worst.

Symptom depth. Does the app track beyond hot flashes and periods? Perimenopause produces cognitive changes, joint pain, sleep disruption, anxiety, heart palpitations, skin changes, digestive issues, and more. An app that only tracks five symptoms is missing most of the clinical picture.

Clinical export. Can you generate a structured report to bring to your doctor? A list of daily entries is not the same as a formatted summary showing patterns, correlations, and trends over time. The export format determines whether your data actually improves your medical appointments.

Evidence basis. Were healthcare professionals involved in the app’s design? This information is sometimes on the app’s website or in academic publications. If there is no mention of clinical involvement, the app was likely built by a software team using assumptions rather than evidence.

Cycle flexibility. Does the app assume regular cycles, or does it accommodate the irregular, unpredictable patterns that define perimenopause? An app that flags “late period” when your cycle shifts from 28 to 45 days is encoding the wrong model of your body.

The Market Is Growing but Quality Is Not Keeping Pace

The digital menopause market is projected to reach $2-4 billion by the early 2030s, according to Verified Market Research. Investment is flowing in. The number of apps is growing.

But more money does not mean better apps. More entrants means more options, but the Birkby review’s 3.1 average suggests new apps are not better than what already exists. The incentives reward user acquisition and engagement metrics, not clinical rigor or privacy.

We built Horiva to fill this gap. On-device storage means your symptom data never leaves your phone unless you export it. The tracking model was designed for perimenopause from the start, not adapted from a period tracker, so it captures the full symptom range without assuming regular cycles. Exportable clinical reports turn your daily tracking into structured evidence that changes medical conversations.

The 77.3% of apps without an evidence base are not going to fix themselves. The market will keep growing. The question is whether you are picking from the 22.7% that took clinical quality seriously, or from the rest.